57 results about "Angiopoietin 2" patented technology

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed.

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

This invention relates to compounds, compositions, and methods useful for modulating Angiopoietin gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Angiopoietin gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Angiopoietin genes, such as Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), Angiopoietin-3 (Ang-3), and Angiopoietin-4 (Ang-4).

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and / or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF / VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF / VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF / VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and / or complementary determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobin molecules and monoclonal antibodies.

The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed.

The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2 / Dll4 binders and anti-VEGF agents for use in treating diseases like cancer and ocular diseases.

The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with solid tumors, like colorectal cancer, and for monitoring the progression of solid tumors, like colorectal cancer, in a subject. Moreover, the present invention relates to a method for stratification of therapy regimen of a subject afflicted with solid tumor entities, such as colorectal cancer, for determining its susceptibility to the treatment with an inhibitor of angiogenesis. Further, the present invention relates to kits allowing performance of the above methods. In particular, the present invention is based on the finding that determining the level or amount of angiopoietin-2 protein in a sample of a subject is useful for conducting the above referenced methods.

The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with solid tumors, like colorectal cancer, and for monitoring the progression of solid tumors, like colorectal cancer, in a subject. Moreover, the present invention relates to a method for stratification of therapy regimen of a subject afflicted with solid tumor entities, such as colorectal cancer, for determining its susceptibility to the treatment with an inhibitor of angiogenesis. Further, the present invention relates to kits allowing performance of the above methods. In particular, the present invention is based on the finding that determining the level or amount of angiopoietin-2 protein in a sample of a subject is useful for conducting the above referenced methods.

The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2 / DII4 binders and anti-VEGF-R agents for use in treating diseases like cancer and ocular diseases.

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

The present invention relates to a combination therapy of an antibody specifically binding to Angiopoietin 2 (ANG-2), and an antibody specifically binding to VEGF with an antibody specifically binding to programmed death ligand 1 (PD-L1).

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as wellas methods of making and using the antibodies.

Methods and computer methods used to assess an individual for the prediction of risk of developing a Cardiovascular (CV) Event over a 1 to 5 year period are provided. The methods employ at least two biomarkers selected from MMP12, angiopoietin-2, complement C7, cardiac troponin I, angiopoietin-related protein 4, CCL18 / PARC, alpha-1-antichymotrypsin complex, GDF11 and alpha-2-antiplasmin, or GDF11 in combination with FSTL3. The methods are particularly useful in predicting CV events in patients who suffer from coronary heart disease (CHD).

Methods and compositions for treating ovarian cancer in a patient comprising administering a therapeutically effective amount of an Angiopoictin-2 inhibitor in combination with a taxane.

The invention provides compositions and methods for protecting vascular tissues from injury that occurs, for example, during occlusion of one or more arteries. In some embodiments, the injury is myocardial infarction. The compositions of the invention include combinations of platelet derived growth factor, vascular endothelial growth factor, and angiopoietin-2.

The invention discloses a high flux screening method for screening an angiopoietin 2 receptor kinase inhibitor, which comprises the following steps: 1)establishment and optimization of a screening model of the angiopoietin 2 receptor kinase inhibitor: performing kinases concentration, incubation time, substrate concentration and ATP concentration experiments; 2)model reliability verification with positive drug: selecting kinases with appropriate concentration, ATP Km and substrate Km, respectively adding 2muml kinases and the substrate in each pore, adding 4muml positive drug in each pore according to concentration gradient, adding 2muml ATP for reacting, incubating at room temperature according to optimization time, adding 10muml stopping solution in each pore for stopping the reaction, incubating for 1 hour at room temperature and then detecting, analyzing data to obtain the positive drug IC50; and 3)verification of the high flux screen model: operating according to the above steps, using a Biomek NXP automation sampling apparatus and a Multidrop automatic liquid separator for feeding samples, and then calculating Z factors. The method has the advantages of simpleness and rapidity, high sensitivity, stable and reliable result and good reappearance, and can be used for high flux screening.